Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert Hegeman"'
Autor:
Robert Hegeman, Dhimant Patel, Leah L. Dietrich, Wei Xu, Anne M. Traynor, KyungMann Kim, Sandeep Saha, Amye J. Tevaarwerk, Mark E. Burkard, Josephine Harter, Kari B. Wisinski, Jules H. Blank
Publikováno v:
Clinical Breast Cancer. 16:256-261
Background Estrogen receptor beta (ERβ) is expressed by 50% to 80% of triple-negative breast cancers (TNBC). Agonism of ERβ has antiproliferative effects in TNBC cells expressing ERβ. This phase 2 study evaluated single-agent high-dose estradiol i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eed2ecca3ea1e524843ef5f5588ade70
https://doi.org/10.1016/j.clbc.2016.03.005
https://doi.org/10.1016/j.clbc.2016.03.005
Autor:
Leah L. Dietrich, Varsha Shah, Robert Hegeman, Kari B. Wisinski, Rubina Qamar, KyungMann Kim, Patrick Mansky, Mark E. Burkard, SarahMaria Donohue, Anne M. Traynor, Uchenna O. Njiaju, Amy L. Stella, Amye J. Tevaarwerk, Timothy Goggins
Publikováno v:
Clinical Breast Cancer. 14:205-211
Adjuvant therapy for breast cancer can be improved by increasing dose density. We tested the feasibility of delivering dose-dense docetaxel-cyclophosphamide (TC) in a single-arm phase II trial of 42 patients via the Wisconsin Oncology Network. Treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65ce3a1bf6afe4e59418646cdfb010fe
https://doi.org/10.1016/j.clbc.2013.10.018
https://doi.org/10.1016/j.clbc.2013.10.018
Publikováno v:
Clinical Prostate Cancer. 3:150-156
Prostate cancer is a leading cause of morbidity and mortality among males. Androgen ablation as initial therapy for advanced prostate cancer provides high response rates but does not cure disease, as nearly all men with metastases will eventually pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a71a9535f8d92d656358517e871116b
https://doi.org/10.3816/cgc.2004.n.025
https://doi.org/10.3816/cgc.2004.n.025
Prospective study of work limitations in cancer patients (pts) undergoing curative chemotherapy (CT)
Autor:
Robert Hegeman, Emily Robinson, Kari B. Wisinski, Roger W. Kwong, Adedayo A. Onitilo, Alexandra Dennee, Harish G. Ahuja, Douglas A. Wiegmann, Ranveer Nanad, William A. Conkright, Kevin A. Buhr, Amye J. Tevaarwerk, Mary E. Sesto, Mark E. Burkard
Publikováno v:
Journal of Clinical Oncology. 35:18-18
18 Background: Impaired work performance that when significant leads to decreased productivity (work limitations) contribute to the “financial toxicity” of cancer treatment. Factors influencing work limitations and employment outcomes are poorly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f25a5efbf83aff292dee029299a8c7c
https://doi.org/10.1200/jco.2017.35.5_suppl.18
https://doi.org/10.1200/jco.2017.35.5_suppl.18
Autor:
Peiman Hematti, Fotis Asimakopoulos, Walter L. Longo, Natalie S. Callander, Toby C. Campbell, Jens C. Eickhoff, Robert Hegeman, Shigeki Miyamoto, Ronald S. Go, Paul R. Hutson, Stephanie Markovina, Eliot C. Williams
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN). We incorporated acetyl-l-car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55d524fbce650dfd8602027a97668b5f